Pfizer News | finanzen.ch

Pfizer Aktie VALOR 962004 / ISIN US7170811035

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

03.11.25	Pfizer Files Antitrust Lawsuit Against Metsera, Its Controlling Stockholders And Novo Nordisk (RTTNews)
02.11.25	Pfizer Sues Metsera And Novo Nordisk Over Merger Dispute (RTTNews)
30.10.25	Why Metsera Is Rising In Pre-market? (RTTNews)
20.10.25	Pfizer: XTANDI Plus Leuprolide Cuts Death Risk 40% In High-Risk NmHSPC Phase 3 Study (RTTNews)
10.01.25	Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer (Businesswire)
06.01.25	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
20.12.24	U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer (Businesswire)
19.12.24	Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts (Businesswire)
17.12.24	Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance (Businesswire)
12.12.24	Pfizer Declares First-Quarter 2025 Dividend (Businesswire)
10.12.24	Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance (Businesswire)
05.12.24	Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS (Businesswire)
20.11.24	Pfizer Announces New Chief Scientific Officer and President, Research & Development (Businesswire)
20.11.24	European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors (Businesswire)
14.11.24	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
04.11.24	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
29.10.24	Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance (Businesswire)
23.10.24	Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older (Businesswire)
22.10.24	U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease (Businesswire)
15.10.24	Tim Buckley Elected to Pfizer’s Board of Directors (Businesswire)
11.10.24	U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors (Businesswire)
10.10.24	Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial (Businesswire)
09.10.24	Pfizer Declares Fourth-Quarter 2024 Dividend (Businesswire)
08.10.24	Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024 (Businesswire)
25.09.24	Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets (Businesswire)
20.09.24	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union (Businesswire)
17.09.24	Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts (Businesswire)
14.09.24	Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia (Businesswire)
14.09.24	Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer (Businesswire)
11.09.24	Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024 (Businesswire)
28.08.24	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
27.08.24	Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare (Businesswire)
22.08.24	Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine (Businesswire)
16.08.24	Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age (Businesswire)
12.08.24	Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults (Businesswire)
30.07.24	Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance (Businesswire)
25.07.24	European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B (Businesswire)
24.07.24	Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate (Businesswire)
11.07.24	Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron (Businesswire)
09.07.24	Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development (Businesswire)
01.07.24	Cyrus Taraporevala Elected to Pfizer’s Board of Directors (Businesswire)
27.06.24	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union (Businesswire)
26.06.24	Pfizer Declares Third-Quarter 2024 Dividend (Businesswire)
18.06.24	Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts (Businesswire)
14.06.24	ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma (Businesswire)
12.06.24	Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy (Businesswire)
03.06.24	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
01.06.24	Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/?Refractory Diffuse Large B-cell Lymphoma (DLBCL) (Businesswire)
31.05.24	Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression (Businesswire)
06.05.24	Pfizer Announces New Chief Strategy and Innovation Officer (Businesswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	98.64	2.03 %	K V
CieFinRichemont	161.80	1.95 %	K V
Nestle	77.70	1.07 %	K V
Geberit	591.00	0.68 %	K V
Swiss Life Hldg	876.20	0.44 %	K V
Part Grp Hldg	971.00	-1.16 %	K V
Givaudan	3’254.00	-1.33 %	K V
Alcon	58.96	-1.40 %	K V
Lonza Grp	539.20	-2.71 %	K V
Sika	151.20	-3.82 %	K V

mehr

03.11.25		Wegen Gegengebots für Metsera: Pfizer verklagt Novo Nordisk - Aktien uneins
03.11.25		Ausblick: Pfizer präsentiert Quartalsergebnisse
03.11.25		Oktober 2025: So schätzen Experten die Novartis-Aktie ein
03.11.25		Roche-Aktie freundlich: Forschungserfolg mit Gazyva bei SLE erzielt -- Neues Hämtologie-Portfolio angekündigt
03.11.25		Merck-Aktie: JP Morgan Chase & Co. vergibt Bewertung
03.11.25		SMI-Titel Novartis-Aktie: So viel Gewinn hätte ein Investment in Novartis von vor 3 Jahren eingebracht
03.11.25		DAX 40-Titel Merck-Aktie: So viel hätten Anleger an einem Merck-Investment von vor 5 Jahren verloren
31.10.25		So schätzen die Analysten die Bayer-Aktie im Oktober 2025 ein